Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yun Hwan | - |
dc.contributor.author | Kim, Do Young | - |
dc.date.accessioned | 2021-09-06T11:22:43Z | - |
dc.date.available | 2021-09-06T11:22:43Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106475 | - |
dc.description.abstract | In spite of substantial progress in the management of hepatocellular carcinoma (HCC), suboptimal treatment results are frequently seen in the intermediate and advanced stages of HCC. The current staging system indicates that multinodular HCC without vascular invasion needs to be treated by transarterial chermembolization (TACE) and HCC with vascular nvasion or distant metastasis is linked to sorafenib, an antiangiogenic therapy. Radioembolization with yttrium-90 (Y-90) is a recently introduced liver-directed therapy employing a catheter-based approach. Growing data suggest that Y-90 radioembolization has a potent anticancer effect with negligible adverse events if appropriate pretreatment evaluations including dosimetry, calculation of lung shunt fraction and assessment of vascular anatomy are performed. Retrospective and small prospective studies have shown response rates and survival after Y-90 therapy which are comparable to TACE and sorafenib in the intermediate and advanced stages, respectively. Although a large sample size is necessary to compare the outcome between TACE and radioembolization in intermediate-stage HCC, selected populations, for whom TACE would not be effective, are candidates for testing the role of Y-90 radioembolization. A multidisciplinary, combined approach in advanced HCC using loco-regional therapy such as radioembolization and systemic therapy including sorafenib also has to be investigated. copyright (C) 2013 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | INTERNAL RADIATION | - |
dc.subject | PARTITION MODEL | - |
dc.subject | LIVER-CANCER | - |
dc.subject | MICROSPHERES | - |
dc.subject | SAFETY | - |
dc.subject | CHEMOEMBOLIZATION | - |
dc.subject | EFFICACY | - |
dc.subject | RECOMMENDATIONS | - |
dc.subject | BRACHYTHERAPY | - |
dc.subject | MANAGEMENT | - |
dc.title | Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yun Hwan | - |
dc.identifier.doi | 10.1159/000345887 | - |
dc.identifier.wosid | 000315323300006 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, v.84, pp.34 - 39 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.citation.title | ONCOLOGY | - |
dc.citation.volume | 84 | - |
dc.citation.startPage | 34 | - |
dc.citation.endPage | 39 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INTERNAL RADIATION | - |
dc.subject.keywordPlus | PARTITION MODEL | - |
dc.subject.keywordPlus | LIVER-CANCER | - |
dc.subject.keywordPlus | MICROSPHERES | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | BRACHYTHERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Yttrium-90 | - |
dc.subject.keywordAuthor | Transarterial chemoembolization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.